Treatment of neuroendocrine carcinoma of the cervix with a PARP inhibitor based on next generation sequencing.

ABSTRACT: •This case reports the treatment of neuroendocrine carcinoma of the cervix with a PARPi based on NGS.•NGS reports have demonstrated somatic mutations BRCA in neuroendocrine carcinoma of the cervix.•The use of a PARPi in neuroendocrine carcinoma of the cervix has not been previously reported.

SUBMITTER: Rose PG 

PROVIDER: S-EPMC6804835 | biostudies-literature | 2019 Nov

REPOSITORIES: biostudies-literature